title: Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs.
abstract: OBJECTIVE
  To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non-neoplastic cells from dogs.
  
  
  METHODS
  3 osteosarcoma and 1 fibroblast cell lines derived from dogs.
  
  
  METHODS
  Cell counts and cell viability assays were performed in cultures of osteosarcoma cells (POS, HMPOS, and COS31 cell lines) and fibroblasts after 24, 48, and 72 hours of incubation with pamidronate at concentrations of 0.001 to 1000 microM or with no drug (control treatment). Percentage viability was determined in cell samples for each concentration of pamidronate and each incubation time. A DNA fragmentation analysis was performed to assess bisphosphonate-induced apoptosis.
  
  
  RESULTS
  Osteosarcoma cell viability decreased significantly in a concentration- and time-dependent manner at pamidronate concentrations ranging from 100 to 1000 microM, most consistently after 48 and 72 hours' exposure. In treated osteosarcoma cells, the lowest percentage cell viability was 34% (detected after 72 hours' exposure to 1000 microM pamidronate). Conversely, 72 hours' exposure to 1000 microM pamidronate did not significantly reduce fibroblast viability (the lowest percentage viability was 76%). After 72 hours of exposure, pamidronate did not cause DNA fragmentation in POS or HMPOS cells.
  
  
  CONCLUSIONS
  Results indicate that pamidronate may have the potential to inhibit osteosarcoma growth in dogs, possibly through a nonapoptotic mechanism. The clinical relevance of these in vitro findings remains to be determined, but administration of pamidronate may potentially be indicated as an adjuvant treatment in chemotherapeutic protocols used in dogs.
authors.affiliation: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610-0126, USA.
authors.forename: Jenna A
authors.initials: JA
authors.lastname: Ashton
authors.forename: James P
authors.initials: JP
authors.lastname: Farese
authors.forename: Rowan J
authors.initials: RJ
authors.lastname: Milner
authors.forename: Linda M
authors.initials: LM
authors.lastname: Lee-Ambrose
authors.forename: James M
authors.initials: JM
authors.lastname: van Gilder
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D004164:Diphosphonates / Q000494:pharmacology*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000187:drug effects; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary*; D000077268:Pamidronate; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate